Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

This report describes the first human study of a novel amyloid‐imaging positron emission tomography (PET) tracer, termed Pittsburgh Compound‐B (PIB), in 16 patients with diagnosed mild AD and 9 controls. Compared with controls, AD patients typically showed marked retention of PIB in areas of association cortex known to contain large amounts of amyloid deposits in AD. In the AD patient group, PIB retention was increased most prominently in frontal cortex (1.94‐fold, p = 0.0001). Large increases also were observed in parietal (1.71‐fold, p = 0.0002), temporal (1.52‐fold, p = 0.002), and occipital (1.54‐fold, p = 0.002) cortex and the striatum (1.76‐fold, p = 0.0001). PIB retention was equivalent in AD patients and controls in areas known to be relatively unaffected by amyloid deposition (such as subcortical white matter, pons, and cerebellum). Studies in three young (21 years) and six older healthy controls (69.5 ± 11 years) showed low PIB retention in cortical areas and no significant group differences between young and older controls. In cortical areas, PIB retention correlated inversely with cerebral glucose metabolism determined with 18F‐fluorodeoxyglucose. This relationship was most robust in the parietal cortex (r = −0.72; p = 0.0001). The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects.

[1]  Albert Gjedde,et al.  High‐ and Low‐Affinity Transport of D‐Glucose from Blood to Brain , 1981, Journal of neurochemistry.

[2]  G. Glenner Alzheimer's disease. The commonest form of amyloidosis. , 1983, Archives of pathology & laboratory medicine.

[3]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  Glenner Gg Alzheimer's disease. The commonest form of amyloidosis. , 1983, Archives of pathology & laboratory medicine.

[5]  R H Huesman,et al.  Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type: Positron Emission Tomography with [1818] Fluorodeoxyglucose , 1983, Journal of computer assisted tomography.

[6]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[7]  C. Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  M J Campbell,et al.  Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  D. Selkoe,et al.  Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. , 1989, The American journal of pathology.

[10]  H. Braak,et al.  Alzheimer's Disease: Striatal Amyloid Deposits and Neurofibrillary Changes , 1990, Journal of neuropathology and experimental neurology.

[11]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[13]  J. Pettegrew,et al.  Development of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease , 1994, Neurobiology of Aging.

[14]  D. Newport,et al.  Evaluation of simulation-based scatter correction for 3-D PET cardiac imaging , 1995 .

[15]  M.E. Casey,et al.  Evaluation of simulation-based scatter correction for 3D PET cardiac imaging , 1995, 1995 IEEE Nuclear Science Symposium and Medical Imaging Conference Record.

[16]  J C Mazziotta,et al.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.

[17]  Richard S. J. Frackowiak,et al.  Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease , 1995, Neuroscience Letters.

[18]  W. März,et al.  Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation , 1995, Neuroscience.

[19]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  J. Price,et al.  Cerebral amyloid deposition and diffuse plaques in ``normal'' aging , 1996, Neurology.

[21]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[22]  R. Elble,et al.  The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease. , 1997, Neuropathology and applied neurobiology.

[23]  L. Thurfjell,et al.  Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. , 1997, Journal of computer assisted tomography.

[24]  Rodger J. Elble,et al.  The distribution of amyloid β protein deposition in the corpus striatum of patients with Alzheimer's disease , 1997 .

[25]  T. Lehtimäki,et al.  Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains , 1997, Neurobiology of Aging.

[26]  P. Hedera,et al.  Neuroimaging of Vessel Amyloid in Alzheimer's Disease a, b , 1997, Annals of the New York Academy of Sciences.

[27]  J. Price,et al.  Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. , 1998, Archives of neurology.

[28]  P. Lansbury,et al.  Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. , 1999, Journal of medicinal chemistry.

[29]  M. Shigeta,et al.  A Follow-Up Study of the Family with the Swedish APP 670/671 Alzheimer’s Disease Mutation , 1999, Dementia and Geriatric Cognitive Disorders.

[30]  G. Bormans,et al.  99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer’s disease , 1999, European Journal of Nuclear Medicine.

[31]  W. Markesbery,et al.  Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. , 1999, Alzheimer disease and associated disorders.

[32]  G. Curran,et al.  Targeting Alzheimer amyloid plaques in vivo , 2000, Nature Biotechnology.

[33]  V. Jelic,et al.  Early Diagnosis of Alzheimer Disease With Positron Emission Tomography , 2000, Alzheimer disease and associated disorders.

[34]  W. Klunk,et al.  X-34, A Fluorescent Derivative of Congo Red: A Novel Histochemical Stain for Alzheimer's Disease Pathology , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[35]  H. Matsuda Cerebral blood flow and metabolic abnormalities in Alzheimer’s disease , 2001, Annals of nuclear medicine.

[36]  J. Price,et al.  Absence of cognitive impairment or decline in preclinical Alzheimer’s disease , 2001, Neurology.

[37]  G. Small,et al.  Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease , 2001, The Journal of Neuroscience.

[38]  W. Klunk,et al.  Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. , 2001, Life sciences.

[39]  J. Trojanowski,et al.  Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. , 2001, Journal of medicinal chemistry.

[40]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[41]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[42]  Brian J Bacskai,et al.  A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. , 2002, Bioorganic & medicinal chemistry letters.

[43]  H. Engler,et al.  Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[45]  W. Klunk,et al.  Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease , 2002, Journal of Molecular Neuroscience.

[46]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[47]  Brian J Bacskai,et al.  Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  William E. Klunk,et al.  The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component , 2003, The Journal of Neuroscience.

[49]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[50]  Bengt Långström,et al.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development , 2003, European Journal of Clinical Pharmacology.

[51]  A. Hirano,et al.  Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease , 2004, Acta Neuropathologica.

[52]  S. Hirai,et al.  Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated byβ protein immunostain , 2004, Acta Neuropathologica.

[53]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.